The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT02245737




Registration number
NCT02245737
Ethics application status
Date submitted
18/09/2014
Date registered
22/09/2014
Date last updated
3/12/2019

Titles & IDs
Public title
An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease
Scientific title
A 24-month, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group, Efficacy, Safety, Tolerability, Biomarker, and Pharmacokinetic Study of AZD3293 in Early Alzheimer's Disease (The AMARANTH Study)
Secondary ID [1] 0 0
I8D-MC-AZES
Secondary ID [2] 0 0
16023
Universal Trial Number (UTN)
Trial acronym
AMARANTH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Alzheimer´s Disease 0 0
Condition category
Condition code
Neurological 0 0 0 0
Alzheimer's disease
Neurological 0 0 0 0
Dementias

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Lanabecestat
Treatment: Drugs - Placebo

Experimental: Lanabecestat 20 milligrams (mg) - Lanabecestat 20 mg given orally once daily for 104 weeks.

Experimental: Lanabecestat 50 mg - Lanabecestat 50 mg given orally once daily for 104 weeks.

Placebo Comparator: Placebo - Placebo given orally once daily for 104 weeks.


Treatment: Drugs: Lanabecestat
Administered orally

Treatment: Drugs: Placebo
Administered orally

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change From Baseline on the 13-item Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog13) - ADAS-Cog13 (13-item version of ADAS-Cog) is a psychometric instrument that evaluates word recall, ability to follow commands, constructional praxis, naming, ideational praxis, orientation, word recognition, memory, comprehension of spoken language, word-finding, and language ability, with a measure of delayed word recall and concentration/ distractibility. The total score of the 13-item scale ranges from 0 to 85, with an increase in score indicating cognitive worsening. Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, apolipoprotein E4 (APOE4) status, acetylcholinesterase inhibitor (AChEI) use at baseline, pooled country, and covariates for baseline ADAS-Cog13 total score, age at baseline, and baseline ADAS-Cog13 total score-by-visit interaction.
Timepoint [1] 0 0
Baseline, Week 104
Secondary outcome [1] 0 0
Change From Baseline on the Alzheimer´s Disease Cooperative Study Activities of Daily Living Inventory Instrumental Items (ADCS-iADL) - The ADCS-ADL is a 23-item inventory developed as a rater-administered questionnaire answered by the participant's caregiver. The ADCS-ADL measures both basic and instrumental activities of daily living by participants. The range for the ADCS-iADL is 0-59 with higher scores reflecting better performance. LS Mean was determined by MMRM model with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline, pooled country, and covariates for baseline for baseline iADL score, age at baseline, and baseline iADL score-by-visit interaction.
Timepoint [1] 0 0
Baseline, Week 104
Secondary outcome [2] 0 0
Change From Baseline on the Functional Activities Questionnaire (FAQ) Score - FAQ is a 10-item, caregiver-based questionnaire and was administered to the study partner who was asked to rate the participant's ability to perform a variety of activities ranging from writing checks, assembling tax records, shopping, playing games, food preparation, traveling, keeping appointments, traveling out of neighborhood, keeping track of current events and understanding media. FAQ total score was calculated by adding the scores from each of the 10 items. Each activity is rated on a scale from 0 to 3 (Never did and would have difficulty now = 1; Never did [the activity] but could do now = 0; Normal = 0; Has difficulty but does by self = 1; Requires assistance = 2; Dependent = 3). FAQ scale is 0 to 30, with higher scores indicating greater impairment. LS Mean was calculated by MMRM with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline and pooled country.
Timepoint [2] 0 0
Baseline, Week 104
Secondary outcome [3] 0 0
Change From Baseline on the Integrated Alzheimer's Disease Rating Scale (iADRS) Score - The iADRS is a composite that measures both cognition and function. The iADRS comprises scores form the ADAS- Cog and the ADCS-iADL. The iADRS is calculated as a linear combination of the total scores of the ADAS-Cog13 (score range 0 to 85 with higher scores reflecting worse performance) and the ADCS-iADL (score range from 0-59 with higher scores reflecting better performance). The iADRS score ranges from 0 to 144 with higher scores indicating greater impairment. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by- visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline, pooled country, and covariates for baseline iADRS13 total score, age at baseline, and baseline iADRS13 total score-by-visit interaction.
Timepoint [3] 0 0
Baseline, Week 104
Secondary outcome [4] 0 0
Change From Baseline on the Clinical Dementia Rating - Sum of Boxes (CDR-SB) Score - The CDR-SB is a rater administered scale and impairment is scored in of the following categories: memory, orientation, judgment and problem solving, community affairs, home and hobbies and personal care. Impairment is scored on a scale in which no dementia = 0, questionable dementia = 0.5, mild dementia = 1, moderate dementia = 2 and severe dementia = 3. The 6 individual category ratings, or "box scores", were added together to give the CDR-Sum of Boxes which ranges from 0-18, with higher scores indicating greater impairment. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline, pooled country, and covariates for baseline CDR-SB score, age at baseline, and baseline CDR-SB score-by-visit interaction.
Timepoint [4] 0 0
Baseline, Week 104
Secondary outcome [5] 0 0
Time to Progression as Measured by Loss of Clinical Dementia Rating (CDR) Global Score Stage - The CDR global score is a composite score calculated using the Washington University CDR-assignment algorithm applied to the 6 individual domain box scores (Morris 1993). The memory domain is considered the primary category that drives the CDR global outcome, and all other domains are secondary. The CDR global score ranges from 0 to 3 (0 = no dementia, 0.5 = questionable dementia, 1 = mild dementia, 2 = moderate dementia, 3 = severe dementia).
Timepoint [5] 0 0
Baseline through Loss of 1 Global Stage or Week 104
Secondary outcome [6] 0 0
Change From Baseline in Neuropsychiatric Inventory (NPI) Score - The NPI is a questionnaire administered to caregivers that quantifies behavioral changes. Each of the 12 behavioral domains the caregiver reports as present are scored for Frequency, scale: 1 (Occasionally) to 4 (Very Frequently), and Severity, scale: 1 (Mild) to 3 (Severe). If the domain is reported by the caregiver as 'Not Affected,' that domain is scored as 0. The individual domain scores are calculated by multiplying the frequency times the severity for each domain. NPI Total Score is calculated by adding the individual domain scores together for all 12 domains, with a scores range from 0 to 144, with higher scores indicating greater severity of neuropsychiatric disturbance. LS Mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline, pooled country, and covariates for baseline NPI score, age at baseline, and baseline NPI score-by-visit interaction.
Timepoint [6] 0 0
Baseline, Week 104
Secondary outcome [7] 0 0
Change From Baseline on the Mini-Mental State Examination (MMSE) - The MMSE is an instrument used to assess a participant's global cognitive function. The MMSE assesses orientation to time and place, immediate and delayed recall of words, attention and calculation, language (naming, comprehension and repetition), and spatial ability (copying a figure). The range for MMSE total Score is 0 to 30, with a higher score indicating better cognitive performance. LS mean was determined by MMRM methodology with factors for treatment, visit, treatment-by-visit interaction, disease status at baseline, APOE4 status, AChEI use at baseline, pooled country, and covariates for baseline MMSE total score, age at baseline, and baseline MMSE total score-by-visit interaction.
Timepoint [7] 0 0
Baseline, Week 104
Secondary outcome [8] 0 0
Pharmacodynamics (PD): Percent Change From Baseline in Concentration of Cerebrospinal Fluid (CSF) Biomarker Amyloid Beta (Aß)1-42 - Concentration of the peptide Aß 1-42 in plasma measured by validated immunoassay. LS Mean was determined by Analysis of covariance (ANCOVA) with last observation carried forward (LOCF), terms for treatment, baseline biomarker and age at baseline.
Timepoint [8] 0 0
Baseline, Week 97
Secondary outcome [9] 0 0
PD: Percent Change From Baseline in Concentration of CSF Biomarker Aß1-40 - Concentration of the peptide Aß 1-40 in plasma measured by immunoassay. LS Mean was determined by ANCOVA with LOCF (last observation carried forward), terms for treatment, baseline biomarker and age at baseline.
Timepoint [9] 0 0
Baseline, Week 97
Secondary outcome [10] 0 0
Change From Baseline in CSF Total Tau - Cerebrospinal fluid samples are collected for analysis of concentration total tau. LS Mean was determined by ANCOVA with LOCF and with factors for treatment, disease status at baseline, baseline biomarker and age at baseline.
Timepoint [10] 0 0
Baseline, Week 97
Secondary outcome [11] 0 0
Change From Baseline in CSF Phosphorylated Tau - Cerebrospinal fluid samples are collected for analysis of concentrations of phosphorylated tau. LS Mean was determined by ANCOVA with LOCF and with factors for treatment, disease status at baseline, baseline biomarker and age at baseline.
Timepoint [11] 0 0
Baseline, Week 97
Secondary outcome [12] 0 0
Change From Baseline in Brain Amyloid Burden Using Florbetapir Amyloid Positron Emission Tomography (PET) Scan - Amyloid deposition in the brain is one of the defining neuropathologic findings of Alzheimer's disease. Florbetapir exhibits high affinity specific binding to amyloid plaques. The change from baseline was measured as average standard uptake value ratio (SUVr) in prespecified regions of interest (ROI) assessed by florbetapir amyloid PET imaging in a subset of participants. The Centiloid scale standardizes quantitative brain amyloid PET results to allow cross-tracer and cross-methodology comparisons. The Centiloid scale anchor points are 0 and 100, where 0 represents a high-certainty amyloid negative scan and 100 represents the amount of global amyloid deposition found in a typical AD scans. Florbetapir SUVr was converted to the Centiloid scale using the following conversion: Florbetapir Centiloids = 183 x SUVr - 177. LS Mean was determined by ANCOVA methodology with factors for treatment, disease status at baseline, baseline biomarker and age at baseline.
Timepoint [12] 0 0
Baseline, Week 104
Secondary outcome [13] 0 0
Change From Baseline in Tau PET ((Flortaucipir F18) - Tau PET tracer (flortaucipir F18) longitudinal study measured whether lanabecestat, in participants with mild AD dementia, affected tau density and distribution over time. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the signal intensity in white matter. Annualized change is derived as change at LOCF divided by (LOCF date - baseline date) multiplied by 365. LS Mean was determined by ANCOVA methodology with factors for treatment, disease status at baseline, baseline biomarker and age at baseline. Baseline defined to be within 28 days of starting study drug.
Timepoint [13] 0 0
Baseline, Week 104
Secondary outcome [14] 0 0
Change From Baseline in Brain Metabolism Using Fluorodeoxyglucose (FDG) - Fluorodeoxyglucose (FDG) PET evaluates the regional brain metabolic rates for glucose as a sensitive, in vivo metabolic index of brain function. The outcome reported is the composite summary of the standard uptake value ratio (SUVR) normalized to the pons + vermis assessed with composite meta and composite meta automated anatomical labeling atlas (ALL). Annualized change is derived as change at LOCF divided by (LOCF date - baseline date) multiplied by 365. LS Mean was determined by ANCOVA methodology with factors for treatment, disease status at baseline, baseline biomarker and age at baseline. Baseline defined to be within 28 days of starting study drug.
Timepoint [14] 0 0
Baseline, Week 104
Secondary outcome [15] 0 0
Change From Baseline in Whole Brain Volume - Magnetic resonance imaging (MRI) was used to evaluate the effect of lanabecestat on whole brain volumes. Annualized change is derived as change at LOCF divided by (LOCF date - baseline date) multiplied by 365. LS Mean was determined by ANCOVA methodology with factors for treatment, baseline vMRI, intracranial volume, disease status at baseline and age at baseline.
Timepoint [15] 0 0
Baseline, Week 104
Secondary outcome [16] 0 0
Pharmacokinetics (PK): Plasma Concentration of Lanabecestat
Timepoint [16] 0 0
Week 4, post dose prior to departure from the clinic

Eligibility
Key inclusion criteria
- Gradual and progressive change in the participant's memory function over more than 6
months, reported by participant and study partner

- Mini-Mental State Examination score of 20-30 inclusive at screening

- Objective impairment in memory as evaluated by memory test performed at screening

- For a diagnosis of mild Alzheimer's Disease (AD), participant meets the National
Institute on Aging and the Alzheimer's Association (NIA-AA) criteria for probable AD

- For a diagnosis of MCI due to AD, participant meets NIA-AA criteria for MCI due to AD
Minimum age
55 Years
Maximum age
85 Years
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Significant neurological disease affecting the central nervous system, other than AD,
that may affect cognition or ability to complete the study, including but not limited
to, other dementias, serious infection of the brain, Parkinson´s disease, or epilepsy
or recurrent seizures

- History of clinically evident stroke, or multiple strokes based on history or imaging
results

- History of clinically important carotid or vertebrobasilar stenosis or plaque

- History of multiple concussions with sustained cognitive complaints or objective
change in neuropsychological function in the last 5 years

- Participants with a current Diagnostic and Statistical Manual of Mental Disorders,
Fifth Edition diagnosis of Major Depressive Disorder or any current primary
psychiatric diagnosis other than AD if, in the judgment of the investigator, the
psychiatric disorder or symptom is likely to confound interpretation of drug effect,
affect cognitive assessments, or affect the participant´s ability to complete the
study

- History of alcohol or drug abuse or dependence (except nicotine dependence) within 2
years before the screening

- Within 1 year before the screening or between screening and baseline, any of the
following: myocardial infarction; moderate or severe congestive heart failure, New
York Heart Association class III or IV; hospitalization for, or symptom of, unstable
angina; syncope due to orthostatic hypotension or unexplained syncope; known
significant structural heart disease (eg, significant valvular disease, hypertrophic
cardiomyopathy), or hospitalization for arrhythmia

- Congenital QT prolongation

- History of cancer within the last 5 years, with the exception of non-metastatic basal
and/or squamous cell carcinoma of the skin, in situ cervical cancer, non-progressive
prostate cancer or other cancers with low-risk of recurrence or spread

- Current serious or unstable clinically important systemic illness that, in the
judgment of the investigator, is likely to affect cognitive assessment, deteriorate,
or affect the participant's safety or ability to complete the study, including
hepatic, renal, gastroenterologic, respiratory, cardiovascular, endocrinologic,
immunologic, or hematologic disorders

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s

The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2/Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,QLD,SA,VIC,WA
Recruitment hospital [1] 0 0
Southern Neurology - Kogarah
Recruitment hospital [2] 0 0
Griffith University - Gold Coast
Recruitment hospital [3] 0 0
Royal Adelaide Hospital - Adelaide
Recruitment hospital [4] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [5] 0 0
Delmont Private Hospital - Glen Iris
Recruitment hospital [6] 0 0
Heidelberg Repatriation Hospital - Heidelberg
Recruitment hospital [7] 0 0
The Florey Institute of Neuroscience and Mental Health - Parkville
Recruitment hospital [8] 0 0
Australian Alzheimer's Research Foundation - Nedlands
Recruitment hospital [9] 0 0
Neuro Trials Victoria Pty Ltd - Noble Park
Recruitment postcode(s) [1] 0 0
2217 - Kogarah
Recruitment postcode(s) [2] 0 0
4222 - Gold Coast
Recruitment postcode(s) [3] 0 0
5000 - Adelaide
Recruitment postcode(s) [4] 0 0
3128 - Box Hill
Recruitment postcode(s) [5] 0 0
3146 - Glen Iris
Recruitment postcode(s) [6] 0 0
3081 - Heidelberg
Recruitment postcode(s) [7] 0 0
3052 - Parkville
Recruitment postcode(s) [8] 0 0
6009 - Nedlands
Recruitment postcode(s) [9] 0 0
3174 - Noble Park
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Connecticut
Country [5] 0 0
United States of America
State/province [5] 0 0
District of Columbia
Country [6] 0 0
United States of America
State/province [6] 0 0
Florida
Country [7] 0 0
United States of America
State/province [7] 0 0
Georgia
Country [8] 0 0
United States of America
State/province [8] 0 0
Illinois
Country [9] 0 0
United States of America
State/province [9] 0 0
Indiana
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Mississippi
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
New Jersey
Country [14] 0 0
United States of America
State/province [14] 0 0
New York
Country [15] 0 0
United States of America
State/province [15] 0 0
North Carolina
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oregon
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
Rhode Island
Country [20] 0 0
United States of America
State/province [20] 0 0
South Carolina
Country [21] 0 0
United States of America
State/province [21] 0 0
Tennessee
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Utah
Country [24] 0 0
United States of America
State/province [24] 0 0
Vermont
Country [25] 0 0
Belgium
State/province [25] 0 0
Limburg
Country [26] 0 0
Belgium
State/province [26] 0 0
Brussels
Country [27] 0 0
Belgium
State/province [27] 0 0
Brussel
Country [28] 0 0
Belgium
State/province [28] 0 0
Edegem
Country [29] 0 0
Belgium
State/province [29] 0 0
Leuven
Country [30] 0 0
Belgium
State/province [30] 0 0
Roeselare
Country [31] 0 0
Canada
State/province [31] 0 0
British Columbia
Country [32] 0 0
Canada
State/province [32] 0 0
Nova Scotia
Country [33] 0 0
Canada
State/province [33] 0 0
Ontario
Country [34] 0 0
Canada
State/province [34] 0 0
Qubec
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
France
State/province [36] 0 0
Cedex 9
Country [37] 0 0
France
State/province [37] 0 0
Bron Cedex
Country [38] 0 0
France
State/province [38] 0 0
Dijon Cedex
Country [39] 0 0
France
State/province [39] 0 0
Lille Cedex
Country [40] 0 0
France
State/province [40] 0 0
Marseille Cedex 05
Country [41] 0 0
France
State/province [41] 0 0
Nantes
Country [42] 0 0
France
State/province [42] 0 0
Paris
Country [43] 0 0
France
State/province [43] 0 0
Toulouse
Country [44] 0 0
France
State/province [44] 0 0
Villeurbanne
Country [45] 0 0
Germany
State/province [45] 0 0
Baden-Württemberg
Country [46] 0 0
Germany
State/province [46] 0 0
Bayern
Country [47] 0 0
Germany
State/province [47] 0 0
Niedersachsen
Country [48] 0 0
Germany
State/province [48] 0 0
Nordrhein-Westfalen
Country [49] 0 0
Germany
State/province [49] 0 0
Saarland
Country [50] 0 0
Germany
State/province [50] 0 0
Sachsen-Anhalt
Country [51] 0 0
Germany
State/province [51] 0 0
Sachsen
Country [52] 0 0
Germany
State/province [52] 0 0
Thüringen
Country [53] 0 0
Germany
State/province [53] 0 0
Berlin
Country [54] 0 0
Hungary
State/province [54] 0 0
Baranya
Country [55] 0 0
Hungary
State/province [55] 0 0
Budapest
Country [56] 0 0
Hungary
State/province [56] 0 0
Debrecen
Country [57] 0 0
Hungary
State/province [57] 0 0
Szeged
Country [58] 0 0
Italy
State/province [58] 0 0
Biella
Country [59] 0 0
Italy
State/province [59] 0 0
Milano
Country [60] 0 0
Italy
State/province [60] 0 0
Palermo
Country [61] 0 0
Italy
State/province [61] 0 0
PI
Country [62] 0 0
Italy
State/province [62] 0 0
Ancona
Country [63] 0 0
Italy
State/province [63] 0 0
Brescia
Country [64] 0 0
Italy
State/province [64] 0 0
Chieti
Country [65] 0 0
Italy
State/province [65] 0 0
Genova
Country [66] 0 0
Italy
State/province [66] 0 0
Modena
Country [67] 0 0
Italy
State/province [67] 0 0
Roma
Country [68] 0 0
Italy
State/province [68] 0 0
Torino
Country [69] 0 0
Japan
State/province [69] 0 0
Aichi
Country [70] 0 0
Japan
State/province [70] 0 0
Chiba
Country [71] 0 0
Japan
State/province [71] 0 0
Hokkaido
Country [72] 0 0
Japan
State/province [72] 0 0
Ibaraki
Country [73] 0 0
Japan
State/province [73] 0 0
Iwate
Country [74] 0 0
Japan
State/province [74] 0 0
Kanagawa
Country [75] 0 0
Japan
State/province [75] 0 0
Kyoto
Country [76] 0 0
Japan
State/province [76] 0 0
Nagano
Country [77] 0 0
Japan
State/province [77] 0 0
Okayama
Country [78] 0 0
Japan
State/province [78] 0 0
Okinawa
Country [79] 0 0
Japan
State/province [79] 0 0
Osaka
Country [80] 0 0
Japan
State/province [80] 0 0
Saitama
Country [81] 0 0
Japan
State/province [81] 0 0
Tokyo
Country [82] 0 0
Japan
State/province [82] 0 0
Toyama
Country [83] 0 0
Japan
State/province [83] 0 0
Fukuoka
Country [84] 0 0
Korea, Republic of
State/province [84] 0 0
Busan
Country [85] 0 0
Korea, Republic of
State/province [85] 0 0
Geonggi-do
Country [86] 0 0
Korea, Republic of
State/province [86] 0 0
Gyeonggi-do
Country [87] 0 0
Korea, Republic of
State/province [87] 0 0
Gyeonggido
Country [88] 0 0
Korea, Republic of
State/province [88] 0 0
Incheon
Country [89] 0 0
Korea, Republic of
State/province [89] 0 0
Seoul
Country [90] 0 0
Poland
State/province [90] 0 0
Dolnoslaskie
Country [91] 0 0
Poland
State/province [91] 0 0
Lódzkie
Country [92] 0 0
Poland
State/province [92] 0 0
Podlaskie
Country [93] 0 0
Poland
State/province [93] 0 0
Bydgoszcz
Country [94] 0 0
Poland
State/province [94] 0 0
Katowice
Country [95] 0 0
Poland
State/province [95] 0 0
Kielce
Country [96] 0 0
Poland
State/province [96] 0 0
Krakow
Country [97] 0 0
Poland
State/province [97] 0 0
Lublin
Country [98] 0 0
Poland
State/province [98] 0 0
Siemianowice Slaskie
Country [99] 0 0
Poland
State/province [99] 0 0
Warszawa
Country [100] 0 0
Puerto Rico
State/province [100] 0 0
Bayamon
Country [101] 0 0
Puerto Rico
State/province [101] 0 0
Carolina
Country [102] 0 0
Puerto Rico
State/province [102] 0 0
San Juan
Country [103] 0 0
Romania
State/province [103] 0 0
Bucuresti
Country [104] 0 0
Romania
State/province [104] 0 0
Timisoara
Country [105] 0 0
Spain
State/province [105] 0 0
Alicante
Country [106] 0 0
Spain
State/province [106] 0 0
Barcelona
Country [107] 0 0
Spain
State/province [107] 0 0
Caceres
Country [108] 0 0
Spain
State/province [108] 0 0
Getafe
Country [109] 0 0
Spain
State/province [109] 0 0
Madrid
Country [110] 0 0
Spain
State/province [110] 0 0
Vizcaya
Country [111] 0 0
Spain
State/province [111] 0 0
Cordoba
Country [112] 0 0
Spain
State/province [112] 0 0
Palma de Mallorca
Country [113] 0 0
Spain
State/province [113] 0 0
Reus
Country [114] 0 0
Spain
State/province [114] 0 0
San Sebastian
Country [115] 0 0
Spain
State/province [115] 0 0
Valencia
Country [116] 0 0
United Kingdom
State/province [116] 0 0
Devon
Country [117] 0 0
United Kingdom
State/province [117] 0 0
East Sussex
Country [118] 0 0
United Kingdom
State/province [118] 0 0
Hampshire
Country [119] 0 0
United Kingdom
State/province [119] 0 0
Lancs
Country [120] 0 0
United Kingdom
State/province [120] 0 0
Leeds
Country [121] 0 0
United Kingdom
State/province [121] 0 0
Staffordshire
Country [122] 0 0
United Kingdom
State/province [122] 0 0
Brentford
Country [123] 0 0
United Kingdom
State/province [123] 0 0
Glasgow
Country [124] 0 0
United Kingdom
State/province [124] 0 0
London
Country [125] 0 0
United Kingdom
State/province [125] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
AstraZeneca
Address
Country
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Eli Lilly and Company
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the efficacy and safety of lanabecestat compared with
placebo administered for 104 weeks in the treatment of early Alzheimer´s disease. The study
will test the hypothesis that lanabecestat is a disease-modifying treatment for participants
with early Alzheimer´s disease, defined as the continuum of participants with mild cognitive
impairment (MCI) due to Alzheimer´s disease and participants diagnosed with mild dementia of
the Alzheimer´s type, as measured by change from baseline on the 13-item Alzheimer's Disease
Assessment Scale - Cognitive Subscale (ADAS-Cog13) score at week 104 in each of the 2
lanabecestat treatment groups compared with placebo.
Trial website
https://clinicaltrials.gov/show/NCT02245737
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon- Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

Summary results
For IPD and results data, please see https://clinicaltrials.gov/show/NCT02245737